

# Subclinical Anxiety: Presence and Implications in Hypertensive Patients

N Agarwal, S Agarwal

## Citation

N Agarwal, S Agarwal. *Subclinical Anxiety: Presence and Implications in Hypertensive Patients*. The Internet Journal of Cardiology. 2012 Volume 10 Number 2.

## Abstract

Hypertension is increasing in prevalence both in developed and in developing countries. It is a major cause of morbidity and mortality, responsible for approximately one half of the health burden and costs worldwide. Its etiology is multi-factorial, with many genetic, environmental, and lifestyle factors playing a role. Psychosocial factors such as anxiety and depression also appear to impact its clinical expression and direction. Anxiety and hypertension frequently coexist. Patients with clinically diagnosed anxiety appear to suffer from not only a higher overall mortality compared to non-anxious people, but they also suffer from a higher incidence of cardiovascular diseases (CVD). In patients with diagnosed cardiovascular events, anxiety levels are high and prognosticate worse outcomes. Research suggests that subclinical anxiety exhibits similar cognitive, neurobiological, and behavioral components when compared to clinical anxiety. However, the presence of subclinical anxiety in hypertensive patients has not been studied well. Our study finds that a significant number of patients with hypertension suffer from subclinical anxiety. This finding has therapeutic and prognostic significance.

## INTRODUCTION

Hypertension is a steadily growing health challenge in the United States. It is estimated that up to 50 million people in the United States suffer from hypertension.<sup>1,2</sup>

Prehypertension, defined as systolic blood pressure 120-139 mm Hg and diastolic blood pressure 80-89 mm Hg, is even more prevalent. A 2005 survey of Americans found that in the population aged 20 years or older, an estimated 41.9 million men and 27.8 million women were suffering from pre-hypertension.<sup>3</sup> Prehypertension is not benign and is associated with twice the risk of future CVD as those with lower blood pressure. In spite of extensive research and widespread patient education, 30% of the adults are still unaware of their hypertension, 40% are not receiving treatment and almost 67% of the treated hypertensives not achieving a treatment goal of bringing the blood pressure to less than 140/90 mm Hg.<sup>1</sup> It remains a major cause of morbidity and mortality, being responsible for two thirds of all strokes and one half of all ischemic heart disease.<sup>4</sup> However, substantial improvements in treatment continue to reduce this hypertension related morbidity and mortality.

Hypertension has also reached epidemic proportions worldwide. Overall, approximately 20% of the world's adults are estimated to have hypertension.<sup>5</sup> The prevalence dramatically increases in patients older than 60 years and

approaches 50%. It is responsible for approximately one half of the health burden and costs worldwide.<sup>6</sup> In 2001, approximately 54% of all strokes and 47% of all ischemic heart disease related deaths worldwide were attributable to systolic hypertension.<sup>7</sup> Further, these hypertension related deaths are expected to increase by over 60% by 2025, rising from 972 million to 1.56 billion worldwide.<sup>8</sup>

The development of primary hypertension is multi-factorial and complex. It is dependent on multiple genes with a largely unknown system of inheritance.<sup>9,10</sup> The exact mechanism on the over-expression or under-expression of several hypertension related genes and the intermediary phenotypes remains poorly understood.<sup>11</sup> However, the environmental and lifestyle factors that increase blood pressure are well known and include obesity, insulin resistance, high alcohol intake, high salt intake, aging, sedentary lifestyle, stress, low potassium intake, and low calcium intake. When present together, many of these factors have an additive and deleterious effect.<sup>12,13</sup> Primary hypertension accounts for 90-95% of all adult cases. The causes of secondary hypertension include renal disease, primary hyper-aldosteronism, Cushing's syndrome, pheochromocytoma, coarctation of the aorta, estrogen use, pregnancy and rare genetic causes, such as Liddle syndrome.

Psychosocial factors such as anxiety also play a role in the clinical course of primary hypertension. Anxiety is common in hypertensive patients.<sup>14</sup> A mechanistic link appears to exist between the presence of anxiety and increased risk of morbidity and mortality due to cardiovascular events in patients with hypertension.<sup>15-18</sup> Although symptomatic anxiety is usually diagnosed and treated, subclinical anxiety may remain undiagnosed. This study was undertaken to evaluate the presence of subclinical anxiety in treated hypertensive patients.

### METHODS


One hundred consecutive hypertensive patients under treatment were evaluated. Hypertension had been diagnosed when the average of 2 or more diastolic BP measurements on at least 2 subsequent visits was  $\geq 90$  mm Hg or when the average of several systolic BP readings on 2 or more subsequent visits was consistently  $\geq 140$  mm Hg. Anti-hypertensive treatment was prescribed according to established therapeutic guidelines. Patients without clinically diagnosed anxiety were given the self administered Zung Self-Rating Anxiety Scale test (SAS). (19) Designed by William W. K. Zung, from Duke University, it is a reliable self administered method to quantify a patient's level of anxiety. All patients were given the 20 item SAS exam during their routine office visit. The test allows the patients to self-report measures of anxious symptoms experienced within the last week. Each item was recorded on a four-point Likert scale, ranging from occurring none or a little of the time to most of the time. Responses were then summed to calculate a total score. The scores (20-80) are classified as follows: normal range: 20-44; mild anxiety: 45-59; moderate anxiety: 60-74 and severe anxiety: 75-80.

### RESULTS

Of the 100 patients, there were 52 (52.0%) females and 48 (48.0%) males. Their ages ranged from 29 to 95 years. Of these, 28 (28.0%) [16 (57.1%) females; 12 (42.9%) males] had anxiety scores over 45, indicating presence of anxiety. Of these 28 patients, 24 (85.7%) [15 (62.5%) females; 9 (37.5%) males] had mild anxiety and 4 (14.3%) [1 (25.0%) female; 3 (75.0%) males] had moderate anxiety. None had severe anxiety. (Figure 1) The absence of severe anxiety in this group was expected as these patients had probably been diagnosed with overt clinical anxiety and were probably excluded at the outset.

**Figure 1**

Figure 1. Distribution of Anxiety



### DISCUSSION

Anxiety is a negative emotion characterized by an emotional paralysis when confronted with a threat. This inability to predict, control or gain preferred results may be to external or internal threats, and can be real or imagined.<sup>20-22</sup> Patients with subclinical anxiety manifest increased neurobiological complications,<sup>20-23</sup> and also suffer from a higher incidence of cardiovascular events.<sup>24</sup> Patients with clinically diagnosed anxiety appear to suffer from a higher overall mortality when compared to non-anxious people.<sup>25-27</sup> This is partly due to an increased incidence of cardiovascular disease in these patients.<sup>15, 28-29</sup> There is a strong association between anxiety and the risk of fatal coronary artery disease.<sup>30,31</sup>

The presence of anxiety is common in hypertensive patients.<sup>14</sup> It may play a role in the pathogenesis of 'white coat hypertension'<sup>32</sup> It is present in about 20% to 25% of patients diagnosed with a cardiovascular disease, even in the absence of an adverse events or invasive interventions.<sup>33</sup> Its presence appears to hasten the development of future cardiac events. Anxiety prevalence approaches 70% to 80% amongst patients who have experienced an acute cardiac event and it persists over the long term in about 20% to 25% of these patients.<sup>18,34,35</sup> Anxiety has negative prognostic consequences in these patients with poor outcomes.<sup>36-40</sup> It interferes with medication, diet and activity compliance and self care abilities.<sup>41-43</sup> Its interferes with their sexual activity.<sup>44</sup> They are more likely to remain disabled and not return to work.<sup>45</sup> Although not well studied, it would appear that subclinical anxiety may be associated with similar consequences.

The mediating mechanisms between the negative consequences of anxiety on cardiovascular system are several, including an over-activity of the sympathetic nervous system, an increase in inflammatory markers, frequent sleep interruption and abnormalities of endothelial function. Additionally, behavioral mechanisms including non-compliance with treatment also results in poor outcomes in these patients.

## CONCLUSIONS

Physicians need to be cognizant of the deleterious effects of anxiety on the heart. Clinical assessment of anxiety may be relevant in the management of hypertensive patients. Subclinical anxiety is occult, but can be recognized by performing a simple office based psychological assessment. Our study shows that almost one out of three hypertensive patients demonstrate sub-clinical anxiety on testing. Diagnosis of subclinical anxiety in hypertensive patients and early therapeutic interventions may decrease the risk of subsequent cardiac events in this population. In patients with a history of cardiovascular events, it may help enhance recovery and reduce the risk of future recurrent events.

## References

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. Dec 2003; 42(6):1206-52.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. *JAMA*. Jul 9 2003; 290(2):199-206.
3. Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. *Med Sci Monit*. Sep 2005; 11(9):CR403-9.
4. Lawes C, Hoorn S, Law M, Elliott P, MacMahon S, Rodgers A. High blood pressure. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Vol. 1. Geneva: World Health Organization; 2004: 281-389.
5. Hajjar I, Kotchen J, Kothcen T. Hypertension: trends in prevalence, incidence and control. *Annu Rev Public Health*. 2006; 27:465-490.
6. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. *Lancet*. 2007; 370,1929-1938.
7. Williams B. The year in hypertension. *J. Am. Coll. Cardiol*. 2009; 55, 65-73.
8. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. *Lancet*. 2005; 365,217-223 .
9. Dungan JR, Conley YP, Langae TY, Johnson JA, Kneipp SM, Hess PJ, et al. Altered beta-2 adrenergic receptor gene expression in human clinical hypertension. *Biol Res Nurs*. Jul 2009; 11(1):17-26.
10. Rule AD, Fridley BL, Hunt SC, Asmann Y, Boerwinkle E, Pankow JS, et al. Genome-wide linkage analysis for uric acid in families enriched for hypertension. *Nephrol Dial Transplant*. Aug 2009; 24(8):2414-20
11. Luft FC. Molecular genetics of human hypertension. *J Hypertens*. 1998; 16:1871-1878
12. INTERSALT Co-operative Research Group. Sodium, potassium, body mass, alcohol and blood pressure: the INTERSALT study. *J Hypertens*. 1988; 6(suppl. 4):S584-S586
13. Sever PS, Poulter NR. A hypothesis for the pathogenesis of essential hypertension: the initiating factors. *J Hypertens*. 1989; 7(suppl 1):S9-S12.
14. Vetere G, Ripaldi L, Ais E, Korob G, Kes M, Villamil A. Prevalence of anxiety disorders in patients with essential hypertension. *Vertex*. 2007 Jan-Feb;18(71): 20-5.
15. Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease: the Normative Aging Study. *Circulation*. 1994; 90: 2225-2229.
16. Roest AM, Martens EJ, de Jonge P, et al. Anxiety and risk of incident coronary heart disease. A meta-analysis. *J Am Coll Cardiol*. 2010; 56:38-46.
17. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation*. 1999; 99: 2192-2217.
18. Moser DK, Dracup K. Is anxiety early after myocardial infarction associated with subsequent ischemic and arrhythmic events? *Psychosom Med*. 1996; 58:395-401
19. Zung WWK. A rating instrument for anxiety disorders. *Psychosomatics*. 1971; 12(6): 371-379
20. Kubzansky LD, Kawachi I, Weiss ST, Sparrow D. Anxiety and coronary heart disease: a synthesis of epidemiological, psychological, and experimental evidence. *Ann Behav Med*.1998; 20: 47-58.
21. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation*. 1999;99: 2192-2217.
22. Barlow DH. *Anxiety and Its Disorders*. New York, NY: Guilford Press; 1988.
23. Smith TW, Ruiz JM. Psychosocial influences on the development and course of coronary heart disease: current status and implications for research and practice. *J Consult Clin Psychol*. 2002; 70: 548-568)
24. Kubzansky LD, Kawachi I, Spiro A III, Weiss ST, Vokonas PS, Sparrow D. Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. *Circulation*. 1997; 95: 818-824.
25. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder. A comparison with primary unipolar depression. *Arch Gen Psychiatry*.1982; 39:701-703.
26. Weissman MM, Markowitz JS, Ouellette R, Greenwald S, Kahn JP. Panic disorder and cardiovascular/cerebrovascular problems: results from a community survey. *Am J Psychiatry*. 1990; 147: 1504-1508.
27. Coryell W, Noyes R, Hause JD. Mortality among outpatients with anxiety disorders. *Am J Psychiatry*. 1986; 143: 508-510.
28. Kuper H, Marmot M, Hemingway H. Systematic review of prospective cohort studies of psychosocial factors in the aetiology and prognosis of coronary heart disease: Marmot M, Elliott P, editors. *Coronary Heart Disease Epidemiology from Aetiology to Public Health*. New York: Oxford University Press; 2005. pp. 363-413.
29. Rafanelli C, Roncuzzi R, Ottolini F, Rigatelli M. Psychological factors affecting cardiologic conditions. *Adv Psychosom Med*. 2007;28: 72-108.
30. Haines AP, Imeson JD, Meade TW. Phobic anxiety and ischaemic heart disease. *Br Med J*. 1987; 295: 297-299.
31. Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, Stampfer MJ, Willett WC. Prospective study of phobic anxiety and risk of coronary heart disease in men. *Circulation*. 1994; 89: 1992-1997.
32. Robert A. Carels, PhD; Andrew Sherwood, PhD; James A. Blumenthal, PhD. High Anxiety and White Coat Hypertension. *JAMA*. 1998;279(3): 197-198.
33. Januzzi JL Jr, Stern TA, Pasternak RC, DeSanctis RW. The influence of anxiety and depression on outcomes of patients with coronary artery disease. *Arch Intern Med*. 2000; 160: 1913-1921.

34. Crowe JM, Runions J, Ebbesen LS, Oldridge NB, Streiner DL. Anxiety and depression after acute myocardial infarction. *Heart Lung*. 1996; 25:98-107.
35. Moser DK, McKinley S, Riegel B, Doering LV, Garvin BJ. Perceived control reduces in-hospital complications associated with anxiety in acute myocardial infarction [abstract].
36. Malan SS. Psychosocial adjustment following MI: current views and nursing implications. *J Cardiovasc Nurs*. 1992; 6(4): 57-70.;
37. Mayou RA, Gill D, Thompson DR, Day A, Hicks N, Volmink J, Neil A. Depression and anxiety as predictors of outcome after myocardial infarction. *Psychosom Med*. 2000; 62:212-219.
38. Moser DK, Dracup K. Psychosocial recovery from a cardiac event: the influence of perceived control. *Heart Lung*. 1995; 24: 273-280.
39. Rozanski A, Bairey CN, Krantz DS, et al. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. *N Engl J Med*. 1988; 318:1005-1012.
40. Rozanski A, Krantz DS, Bairey CN. Ventricular responses to mental stress testing in patients with coronary artery disease: pathophysiological implications. *Circulation*. 1991; 83(4 suppl):III137-III144
41. Maeland JG, Havik OE. After the myocardial infarction: a medical and psychological study with special emphasis on perceived illness. *Scand J Rehabil Med Suppl*. 1989; 22: 1-87
42. Rose SK, Conn VS, Rodeman BJ. Anxiety and self-care following myocardial infarction. *Issues Ment Health Nurs*. 1994; 15: 433-444.
43. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Predictors of attendance at cardiac rehabilitation after myocardial infarction. *J Psychosom Res*. 2001; 51: 497-501.
44. Rosal MC, Downing J, Littman AB, Ahern DK. Sexual functioning post-myocardial infarction: effects of beta-blockers, psychological status and safety information. *J Psychosom Res*. 1994; 38: 655-667.
45. Havik OE, Maeland JG. Patterns of emotional reactions after a myocardial infarction. *J Psychosom Res*. 1990; 34: 271-285.

**Author Information**

**Neil K. Agarwal**

Medical Student, St Georges University

**Shashi K. Agarwal, MD**

Cardiologist, St. Michael's Medical Center